The UK and US have secured a important commercial pact that will preserve zero tariffs on British medicine products going into the US market.
The Terms of the Deal
As part of the deal, the UK has committed to increase spending on drugs through the public health system. This commitment ensures that duties on these vital exports will be held at nothing for a duration of three years.
This development is in response to recent threats to dramatically increase tariffs on branded pharmaceutical products, with increases floated reaching 100%.
"This agreement between the Britain bolsters the international landscape for innovative medicines and brings much-needed balance to transatlantic medicine commerce," a release said.
Commercial Impact
Medicines represent one of the the United Kingdom's biggest export categories to the America, which is clearly the largest market for large UK drugmakers.
Export figures show that in the one-year period to the end of last September, the UK sold drugs worth billions to the US. This figure represented 17.4% of all goods exports in that period.
"This deal secures jobs, increases funding and paves the way for the UK to become a global hub for medical research," a government official stated.
Key NHS Changes
The deal involves several specific changes from the UK:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it judges new treatments to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a target to double overall NHS spending on treatments from 0.3 percent of GDP to 0.6% over the next decade.
- Payback Limit: The amount pharmaceutical firms must pay back to the NHS to control costs will be capped at 15%. Previously, repayments exceeded twenty percent.
Broader Context
The deal comes amid a protracted tension between the pharmaceutical industry and the British authorities over drug pricing and regulatory access.
This friction were intensified by arguments that American consumers were paying significantly more for the same drugs than consumers in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been halted or scrapped, while substantial expansions have been directed toward US facilities.
The Science Minister stated that the NHS had to invest a greater share on drugs, noting that its expenditure on drugs had decreased as a share of its overall budget over the last ten years.
